Le Lézard
Classified in: Health
Subjects: PDT, FDA

Water Street's Partnership with Leading Medical Products Company Leads to FDA Approval and Commercial Launch of Clindamycin in 0.9% Sodium Chloride Injection


CHICAGO, June 7, 2017 /PRNewswire/ -- Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced today that its development partnership with a leading medical products company has resulted in the U.S. Food and Drug Administration (FDA) approval and commercial launch of ready-to-use clindamycin injection in saline. 

Water Street's company, Celerity Pharmaceuticals, LLC, is funding and leading the development and approval of nine product families using its partner's proprietary container technology, enhanced packaging platform, and aseptic filling manufacturing process. Following FDA approval of this new product, Celerity transferred ownership of the NDA to its partner, which today announced the commercial launch of the product in the United States. The approval of clindamycin in saline is the third molecule developed and approved as part of this joint effort.

"We are honored to be entrusted by our partner with funding and developing clindamycin and other important drug products," said Al Heller, operating partner with Water Street and chairman of Celerity.  "Our team's years of experience operating and growing pharmaceutical businesses along with Dan Robins' strong leadership of the Celerity development team continues to make this unique collaboration successful. We look forward to continuing to work with our partners to support their goals."

About Water Street

Water Street is a strategic investor focused exclusively on health care. The firm has a strong record of building market-leading companies across key growth sectors in health care. It has worked with some of the world's leading health care companies on its investments including Johnson & Johnson, Medtronic, Smith & Nephew and Walgreen Co. Water Street's team is comprised of industry executives and investment professionals with decades of experience investing in and operating global health care businesses. The firm is headquartered in Chicago. For more information about Water Street, visit waterstreet.com.

 

SOURCE Water Street Healthcare Partners


These press releases may also interest you

at 11:15
Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market....

at 11:15
Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product. Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of NIOPEG® (a...

at 11:00
PRESS RELEASE FOR IMMEDIATE PUBLICATION 19 April 2024 Dr. Sam Barrell CBE appointed as CEO of LifeArc LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer. Sam's appointment follows an extensive...

at 11:00
MasterControl, a leading provider of quality management and manufacturing execution software for life sciences, announced it has been recognized by the Imapac 2024 Asia-Pacific Biopharma Excellence Awards in the "Best Bioprocessing Supplier:...

at 10:36
Senstar Technologies Corporation , a leading international provider of comprehensive physical, video and access control security products and solutions, announced today that its Annual Report on Form 20-F for the year ended December 31, 2023 has been...

at 10:33
The report titled "Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Global...



News published on and distributed by: